Promaxo, Inc.

Promaxo is a MedTech company specializing in compact, single-sided portable MRI systems and AI-driven technologies for interventional imaging and image-guided procedures. The company's flagship product is an office-based MRI platform that received FDA clearance in March 2021, enabling real-time MR-guided biopsies and cancer treatment in ambulatory settings without requiring dedicated MRI suites. Promaxo's system is designed for urologists and hospitals targeting prostate cancer diagnosis and treatment, featuring AI-driven tissue characterization with reported 77% cancer detection rates and 33% improvement in detecting clinically significant cancers versus standard of care. The system requires minimal facility upgrades and integrates seamlessly into existing clinical workflows, allowing concurrent clinic operations and interventional procedures. Founded in 2016 and backed by strategic investors including MicroPort and Zepp Health, Promaxo holds over 200 patents and is expanding applications to breast oncology and orthopedics. The company is led by CEO and Chairman Amit Vohra.